These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 18674944)

  • 21. Responsiveness of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor alpha inhibitors.
    Pedersen SJ; Sørensen IJ; Hermann KG; Madsen OR; Tvede N; Hansen MS; Thamsborg G; Andersen LS; Majgaard O; Loft AG; Erlendsson J; Asmussen K; Johansen JS; Jurik AG; Møller J; Hasselquist M; Mikkelsen D; Skjødt T; Hansen A; Ostergaard M
    Ann Rheum Dis; 2010 Jun; 69(6):1065-71. PubMed ID: 19740906
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in ankylosing spondylitis: MMP-3 is a reproducibly sensitive and specific biomarker of disease activity.
    Chen CH; Lin KC; Yu DT; Yang C; Huang F; Chen HA; Liang TH; Liao HT; Tsai CY; Wei JC; Chou CT
    Rheumatology (Oxford); 2006 Apr; 45(4):414-20. PubMed ID: 16287916
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety.
    Maksymowych WP; Jhangri GS; Lambert RG; Mallon C; Buenviaje H; Pedrycz E; Luongo R; Russell AS
    J Rheumatol; 2002 May; 29(5):959-65. PubMed ID: 12022358
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Occupational therapy in ankylosing spondylitis: Short-term prospective study in patients treated with anti-TNF-alpha drugs.
    Spadaro A; De Luca T; Massimiani MP; Ceccarelli F; Riccieri V; Valesini G
    Joint Bone Spine; 2008 Jan; 75(1):29-33. PubMed ID: 18029218
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ankylosing spondylitis refractory to tumor necrosis factor blockade responds to tocilizumab.
    Cohen JD; Ferreira R; Jorgensen C
    J Rheumatol; 2011 Jul; 38(7):1527. PubMed ID: 21724733
    [No Abstract]   [Full Text] [Related]  

  • 26. The VEGF and BMP-2 levels in patients with ankylosing spondylitis and the relationship to treatment with tumour necrosis factor alpha inhibitors.
    Tošovský M; Bradna P; Andrýs C; Andrýsová K; Cermáková E; Soukup T
    Acta Medica (Hradec Kralove); 2014; 57(2):56-61. PubMed ID: 25257151
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictive factors for partial remission according to the Ankylosing Spondylitis Assessment Study working group in patients with ankylosing spondylitis treated with anti-TNFα drugs.
    Perrotta FM; Addimanda O; Ramonda R; D'Angelo S; Lubrano E; Marchesoni A; Olivieri I; Punzi L; Salvarani C; Spadaro A
    Reumatismo; 2014 Nov; 66(3):208-14. PubMed ID: 25376955
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Human leukocyte antigen-G in ankylosing spondylitis and the response after tumour necrosis factor-alpha blocker therapy.
    Chen CH; Liao HT; Chen HA; Liu CH; Liang TH; Wang CT; Tsai CY; Chou CT
    Rheumatology (Oxford); 2010 Feb; 49(2):264-70. PubMed ID: 20008091
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The change of bone mineral density according to treatment agents in patients with ankylosing spondylitis.
    Kang KY; Lee KY; Kwok SK; Ju JH; Park KS; Hong YS; Kim HY; Park SH
    Joint Bone Spine; 2011 Mar; 78(2):188-93. PubMed ID: 20621536
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictors of response to anti-TNF therapy in ankylosing spondylitis: results from the British Society for Rheumatology Biologics Register.
    Lord PA; Farragher TM; Lunt M; Watson KD; Symmons DP; Hyrich KL;
    Rheumatology (Oxford); 2010 Mar; 49(3):563-70. PubMed ID: 20032223
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Ankylosing Spondylitis Disease Activity Score is a highly discriminatory measure of disease activity and efficacy following tumour necrosis factor-α inhibitor therapies in ankylosing spondylitis and undifferentiated spondyloarthropathies in China.
    Xu M; Lin Z; Deng X; Li L; Wei Y; Liao Z; Li Q; Wei Q; Hu Z; Zhang Y; Lin Q; Huang J; Li T; Pan Y; Wu Y; Jin O; Yu B; Gu J
    Rheumatology (Oxford); 2011 Aug; 50(8):1466-72. PubMed ID: 21441550
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of TNFα blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis.
    Callhoff J; Sieper J; Weiß A; Zink A; Listing J
    Ann Rheum Dis; 2015 Jun; 74(6):1241-8. PubMed ID: 24718959
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis.
    Brandt J; Khariouzov A; Listing J; Haibel H; Sörensen H; Grassnickel L; Rudwaleit M; Sieper J; Braun J
    Arthritis Rheum; 2003 Jun; 48(6):1667-75. PubMed ID: 12794835
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multicenter validation of the value of BASFI and BASDAI in Chinese ankylosing spondylitis and undifferentiated spondyloarthropathy patients.
    Lin Z; Gu J; He P; Gao J; Zuo X; Ye Z; Shao F; Zhan F; Lin J; Li L; Wei Y; Xu M; Liao Z; Lin Q
    Rheumatol Int; 2011 Feb; 31(2):233-8. PubMed ID: 20012866
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Calprotectin (S100A8/9) as serum biomarker for clinical response in proof-of-concept trials in axial and peripheral spondyloarthritis.
    Turina MC; Yeremenko N; Paramarta JE; De Rycke L; Baeten D
    Arthritis Res Ther; 2014 Aug; 16(4):413. PubMed ID: 25135077
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Radiographic progression is associated with resolution of systemic inflammation in patients with axial spondylarthritis treated with tumor necrosis factor α inhibitors: a study of radiographic progression, inflammation on magnetic resonance imaging, and circulating biomarkers of inflammation, angiogenesis, and cartilage and bone turnover.
    Pedersen SJ; Sørensen IJ; Lambert RG; Hermann KG; Garnero P; Johansen JS; Madsen OR; Hansen A; Hansen MS; Thamsborg G; Andersen LS; Majgaard O; Loft AG; Erlendsson J; Asmussen KH; Jurik AG; Møller J; Hasselquist M; Mikkelsen D; Østergaard M
    Arthritis Rheum; 2011 Dec; 63(12):3789-800. PubMed ID: 22127697
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of ankylosing spondylitis with TNF inhibitors does not have adverse effect on results of liver function tests: a longitudinal study.
    Capkin E; Karkucak M; Cosar AM; Ak E; Karaca A; Gokmen F; Budak BS; Tosun M
    Int J Rheum Dis; 2015 Jun; 18(5):548-52. PubMed ID: 24612551
    [TBL] [Abstract][Full Text] [Related]  

  • 38. TNFalpha antagonist continuation rates in 442 patients with inflammatory joint disease.
    Brocq O; Roux CH; Albert C; Breuil V; Aknouche N; Ruitord S; Mousnier A; Euller-Ziegler L
    Joint Bone Spine; 2007 Mar; 74(2):148-54. PubMed ID: 17368068
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of 14 weeks of TNF alpha blockade treatment on lipid profile in ankylosing spondylitis.
    Mathieu S; Dubost JJ; Tournadre A; Malochet-Guinamand S; Ristori JM; Soubrier M
    Joint Bone Spine; 2010 Jan; 77(1):50-2. PubMed ID: 20022785
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Investigation of effects of two-different treatment modalities on nerve conduction in patients with ankylosing spondylitis.
    Capkin E; Karkucak M; Kose MM; Çakmak VA; Turkyilmaz AK; Tosun M
    Rheumatol Int; 2012 Feb; 32(2):431-4. PubMed ID: 21120488
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.